Robyn Karnauskas
Stock Analyst at Truist Securities
(1.95)
# 2,747
Out of 4,810 analysts
182
Total ratings
41.03%
Success rate
-1.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Hold | $333 → $298 | $293.92 | +1.39% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $51.34 | +26.61% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $79.17 | +38.94% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $106.50 | -22.07% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $179.10 | +17.25% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.62 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $119.26 | +185.09% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.29 | +1,915.50% | 2 | May 15, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $0.97 | +618.24% | 13 | May 13, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $571.06 | +98.75% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.93 | +418.13% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.09 | +191.26% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $14.09 | +425.20% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $10.19 | +125.71% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $15.43 | +211.08% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $7.68 | +551.04% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $754.35 | +12.68% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $495.83 | +2.45% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $22.12 | +62.75% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $45.08 | -44.54% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.92 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $59.67 | +134.62% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $0.83 | +17,981.00% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $0.92 | +657.33% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $9.17 | +499.78% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.91 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $2.44 | +1,088.52% | 1 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $16.80 | +1,804.76% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $2.18 | +588.07% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.37 | +22,935.23% | 1 | Oct 8, 2020 |
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $293.92
Upside: +1.39%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $51.34
Upside: +26.61%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $79.17
Upside: +38.94%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $106.50
Upside: -22.07%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $179.10
Upside: +17.25%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.62
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $119.26
Upside: +185.09%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.29
Upside: +1,915.50%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.97
Upside: +618.24%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $571.06
Upside: +98.75%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.93
Upside: +418.13%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.09
Upside: +191.26%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $14.09
Upside: +425.20%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $10.19
Upside: +125.71%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $15.43
Upside: +211.08%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $7.68
Upside: +551.04%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $754.35
Upside: +12.68%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $495.83
Upside: +2.45%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $22.12
Upside: +62.75%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $45.08
Upside: -44.54%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.92
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $59.67
Upside: +134.62%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $0.83
Upside: +17,981.00%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $0.92
Upside: +657.33%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $9.17
Upside: +499.78%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.91
Upside: -
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $2.44
Upside: +1,088.52%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $16.80
Upside: +1,804.76%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $2.18
Upside: +588.07%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.37
Upside: +22,935.23%